|
Send your comments and tips to whitecoat@globe.com
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« Newton-Wellesley opens joint reconstruction center | Main | Today's Globe: BU lab fire, therapist on trial, tainted hogs, Afghan infant mortality, nursing home oversight » Thursday, April 26, 2007Genetic understanding of diabetes deepensBy Alice Dembner, Globe Staff Four separate scientific teams, including one led by Harvard researchers, are today reporting progress toward unraveling the genetic basis of the most common form of diabetes. They have identified three new genetic risk factors and confirmed five others that were discovered over the last few years. An additional risk factor identified by one group has not yet been confirmed by others. Together, the genetic defects account for about 5 percent of the risk of getting the illness, said David Altshuler, associate professor of genetics and medicine at Harvard Medical School and a leader of one of the four teams that included the Broad Institute of Harvard and MIT. "The picture that is emerging is of multiple genes, each with a modest effect" on diabetes, he said. Overall, genetics account for about half the risk of getting type 2 diabetes, according to Altshuler. Environment and such behaviors as obesity and lack of exercise account for the remaining risk. More than 20 million Americans now have type 2 diabetes and scientists estimate that about 54 million more are at risk of getting the illness. The disease harms the body's ability to control blood sugar and can lead to heart disease, blindness and early death. "The pharmaceutical industry is absolutely salivating at all of these studies because they represent the best validation of a new drug target," said Dr. Francis Collins, director of the National Human Genome Research Institute and a leader of another of the teams. But Collins cautioned that it could be a decade before patients see any new drugs from the research. The results were published today in the online editions of the journals Science and Nature Genetics. They are all based on a new research technique called genome-wide association studies, in which scientists compare genetic samples from thousands of individuals with a specific illness to those without it. Differences between the two are examined as possible genetic causes of the disease. Posted by Karen Weintraub at 02:05 PM
|
